We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisers Have Mixed Views on OCP Models in Pediatric Trials
FDA Advisers Have Mixed Views on OCP Models in Pediatric Trials
March 28, 2012
A key FDA advisory committee unanimously recommended that modeling and simulation methods be considered for use in all pediatric drug development programs, but its enthusiasm was not extended to models touted by the agency’s Office of Clinical Pharmacology (OCP).